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Modulation of sensitivity to cis-diamminedichloroplatinum (II) by
thromboxane A2 receptor antagonists in non-small-cell lung cancer cell lines
K Kasahara, M Fujimura, T Bando, K Shibata, H Shirasaki and T Matsuda
The Third Department ofInternal Medicine, Kanazawa University School ofMedicine, 13-1 Takara-machi, Kanazawa 920, Japan.
Summary We examined the effect of selective thromboxane A2 (TXA2) receptor antagonists, calcium 5(Z)-iR,
2S, 3S, 4S-7-[3-phenylsulphonylaminobicyclo [2.2.1] hept-2-yl]-5-heptonoate hydrate (S-1452) and +-7-(3,5,6,-
trimethyl-1,4-benzoquinon-2-yl)-7-phenylhaptanoic acid (AA-2414), on sensitivity to cis-diamminedichloropla-
tinum (II) (CDDP) in non-small-cell lung cancer cell lines. IC50 values to CDDP using MTT assay were
decreased 2.1- and 4.6-fold respectively by treatment with 250 or 500 gM S-1452, for a 2 h simultaneous drug
exposure, and those of PC-9/CDDP, a CDDP-resistant cell line, were decreased 3.1- and 6.1-fold. Sensitivity to
carboplatin was also enhanced by the treatment with S-1452. IC50 values to CDDP and carboplatin were
decreased by treatment with AA-2414 in a dose-dependent manner. Isobologram analysis showed that the
combination of CDDP with S-1452 or AA-2414 produced supra-additive or additive effects in each cell line.
Neither glutathione content nor glutathione S-transferase activity was changed in either cell line by treatment
with 500 gM S-1452. Accumulation of platinum into PC-9 and PC-9/CDDP was increased by the treatment in a
dose-dependent manner. Na+, K+-ATPase activity of PC-9 and PC-9/CDDP was enhanced by the treatment
of S-1452 in a dose-dependent manner. These data show that the TXA2 receptor antagonists may enhance the
sensitivity of non-small-cell lung cancer cell lines to platinum agents. Increase in Na+, K+-ATPase activity
induced by S-1452 may be the mechanism of its sensitising effect through increase in platinum accumulation.
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Cis-diamminedichloroplatinum (II) (CDDP) is an important
anti-cancer agent for the treatment of lung cancer (Loether et
al., 1984) that is often limited by the development of
resistance. A variety of mechanisms of CDDP resistance
have been described (Andrews and Howell, 1990), including
decreased drug accumulation (Andrews et al., 1988),
increased detoxification by thiol-containing scavenger mole-
cules, such as glutathione (GSH) (Fujiwara et al., 1990) and
metallothionein (Kasahara et al., 1991), and increased repair
of DNA damage (Eastman et al., 1988). In these
investigations resistance mechanism is multifactorial, and
one of the mechanisms more commonly observed is an
accumulation defect (Andrews and Howell, 1990). On the
basis of the above mechanisms of resistance, several strategies
for overcoming the problem have been proposed. These
include the depletion of glutathione (Hromas et al., 1987),
inhibition of DNA repair (Roberts et al., 1986) and increase
in CDDP accumulation (Morikage et al., 1993).
Calcium 5(Z)-1R, 2S, 3S, 4S-7-[3-phenylsulphonylamino-
bicyclo [2.2.1] hept-2-yl]-5-heptonoate hydrate (S-1452) (Dube
et al., 1992), and (±)-7-3(3,5,6,-trimethyl-1,4-benzoquinon-2-
yl)-7-phenylhaptanoic acid (AA-2414) (Kurokawa et al.,
1994) are selective TXA2 receptor antagonists. In this study,
we evaluated the effect of S-1452 and AA-2414 on the
sensitivity of non-small-cell lung cancer cell lines to CDDP
and carboplatin (CBDCA). There was a sensitising effect of
TXA2 receptor antagonists on the cytotoxicity of platinum
agents and we examined the mechanism of the sensitising
effect of TXA2 receptor antagonists.
Materials and methods
Drugs and chemicals
RPMI-1640 and calcium-free and magnesium-free Dulbecco's
phosphate-buffered saline (PBS) were purchased from Nissui
Pharmaceutical, Tokyo, Japan. CDDP and CBDCA were
obtained from the Bristol Myers Squibb, Tokyo, Japan.
Calcium 5(Z)-1R, 2S, 3S, 4S-7-[3-phenylsulphonylaminobicy-
clo [2.2.1] hept-2-yl]-5-heptonoate hydrate (S-1452) (Figure 1)
was obtained from the Shionogi, Osaka, Japan and (±)-7-
(3,5,6,-trimethyl-1, 4-benzoquinon -2 -yl) -7 -phenylhaptanoic
acid (AA-2414) (Figure 1) was obtained from Takeda
Chemical Industries, Tokyo, Japan. These antagonists were
dissolved in dimethylsulphoxide (DMSO) before use. The
maximum concentration of DMSO in each experiment did
not exceed 1%, and this concentration of DMSO did not
influence drug sensitivity, accumulation or enzyme activities
(data not shown). 86Rb as a rubidium chloride and liquid
scintillant (ACS II) were purchased from Amersham Japan
(Tokyo, Japan). All other drugs and chemicals were
purchased from Sigma Chemical Co (St Louis, MO, USA).
Cell lines
PC-9 cell line was derived from a human adenocarcinoma of
lung and established by Dr Y Hayata, Tokyo Medical
College. PC-9/CDDP, a CDDP-resistant cell line, was
established and characterised previously (Fujiwara et al.,
1990). We obtained these cell lines from the Pharmacology
Division, National Cancer Center Research Institute, Tokyo.
The PC-9/CDDP cell line demonstrated cross-resistance
alkylating agents, such as chlorambucil, melphalan and 3-
[(4-amino-2-methyl-5-pyrimidinyl)]methyl- 1-(2-chloroethyl)-1 -
nitrosourea. The GSH content of PC-9/CDDP cells was
increased 3.2-fold compared with PC-9 cells. Treatment with
DL-buthionine-S, R-sulphoximine resulted in partial reversal
of the resistance. Intracellular accumulation in PC-9/CDDP
cells was lower than in PC-9 cells. Fujiwara et al. (1990) have
concluded that the increase in GSH content and decrease in
drug accumulation might be responsible for the resistance of
PC-9/CDDP cells. There is no significant difference in
doubling time (24+2 h in PC-9 and 26+2 h in PC-9/
CDDP) and protein contents (163 + 18 ,ug protein 106 cells
in PC-9 and 180±10,Ig protein 106 cells) between these two
cell lines. The cells were grown in RPMI-1640 medium
supplemented with 10% heat-inactivated fetal bovine serum
(Gibco Laboratories, Grand Island, NY, USA), 100 ,ig ml-1
streptomycin and 100 units ml-' penicillin in a humidified
atmosphere of 5% carbon dioxide and 95% air.
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Figure 1 Chemical structures of S-1452 and AA-2414.
Drug sensitivity test
Drug sensitivities were determined by the MTT assay (Nishio
et al., 1990). Exponentially growing cells were harvested and
suspended in the fresh medium. Cell suspensions adjusted to
2 x 104 cells ml-' were incubated in centrifuge tubes (Costar
3215 Costar Corp., Cambridge, MA, USA). S-1452 and AA-
2414 were dissolved in DMSO and diluted with medium just
before use. The TXA2 receptor antagonists or vehicle were
added to the cell suspension immediately before anti-cancer
agent treatment. After incubation for 2 h at 37°C, cells were
collected by centrifugation, rinsed twice with drug-free
medium and adjusted to 2 x 104 cells ml-'. Treated cells
(2000 per well) were seeded into a 96-well microplate (Falcon
3072, Becton Dickinson, Franklin Lakes, NJ, USA) and
incubated for 96 h. After incubation, MTT dissolved in PBS
at 5 mg ml-' was added to each well at 20gl per well and the
plates were incubated at 37°C for 4 h. After centrifugation at
2000 r.p.m. for 10 min, the supernatant was carefully
aspirated and 200 ,ul of DMSO was added to each well to
dissolve the formazan crystals, followed by shaking for
5 min. Then absorbance of each well at 560 nm was
measured using a scanning microplate spectrophotometer
(EAR 340 AT, SLT, Vienna, Austria). Each experiment was
performed in triplicate and at least three independent times.
The degree of drug sensitivity of each cell line was expressed
as the IC50 value, defined as the drug concentration inhibiting
cell growth by 50% as compared with the control wells.
Isobologram analysis
The effect on the IC50 value of TXA2 receptor antagonists
combined with platinum agents was analysed by an
isobologram method (Steel et al., 1979; Berenbaum, 1989).
GSH and glutathione S-transferase (GST) assays
Total GSH contents were measured by the method of Griffith
(1980). Total GST activity was measured by the method of
Habig et al. (1974) with 1 mM 1-chloro-2,4-dinitrobenzene as
substrate. The effect of S-1452 treatment on GSH content
and GST activity was examined. Samples for the enzyme
assay were prepared by harvesting the exponentially growing
cells treated with 500 ,UM S-1452 for 2 h at 37°C and washing
twice with cold PBS on ice.
Platinum accumulation
For drug accumulation studies, PC-9 and PC-9/CDDP cells
in exponentially growing phase were harvested and seeded in
75 cm2 culture flasks at a density of 2 x 106 cells ml-'. After
1 h preincubation, they were incubated with 50 Mm CDDP
and S-1452 solutions or vehicle for 60 or 120 min. To
examine possible alterations in efflux of CDDP from each cell
line, cells were treated with CDDP for 120 min and washed
twice with fresh medium and incubated for an additional 60
or 120 min. At the end of each time period, cells were
collected by centrifugation and washed with ice-cold PBS
twice. The cell pellets were digested in nitric acid at 80°C for
5 h, and then platinum was chelated with sodium diethyl-
dithiocarbamate followed by extraction with chloroform. The
cell extracts were analysed for platinum by atomic absorption
spectrometry using the Hitachi polarised Zeeman atomic
absorption spectrophotometer, model Z-7000.
'Rb+ influx assay
The Na+, K+-ATPase activities in these cell lines were
determined by measuring 86Rb+ influx as a marker for K+
influx using the method of Ohmori et al. (1994). Briefly, the
harvested cells were resuspended in Hepes buffer (10 mM
glucose, 5 mM potassium chloride, 1 mM magnesium
chloride, 1 mM calcium chloride, 10 mM Hepes hydrochloric
acid, and 123 mM sodium chloride and adjusted to pH 7.4
with Tris base) at a density of 1 x 106 cells ml-'. The medium
was then replaced by 1 ml of Hepes buffer containing 86Rb+
(1 MCi ml-1) preheated at 37°C and mixed by pipetting. To
evaluate the effect of S-1452 on 86Rb+ influx, cells were
treated with S-1452 (250 or 500 gM) or vehicle for 60 min.
The cell suspension was incubated for various times (1, 5, 10,
20 and 60 min) at 37°C and washed twice with ice-cold PBS.
Then, the cell pellets were solubilised with 1 ml of 5%
sodium dodecyl sulphate, and 0.9 ml was mixed with 10 ml of
ACS II. The radioactivity was counted by liquid scintillation
counter. The data were corrected for non-specific absorption
of 86Rb+ by subtracting the radioactivity associated with the
cells at 4°C.
Protein determination
Protein content was determined by the bicinchoninic acid
protein assay (Pierce Chemical, Rockford, IL, USA).
Statistical analysis
Results were expressed as the mean+s.d. Statistical
differences were determined by unpaired Student's t-test. A
P-value of less than 0.05 was considered significant.
Results
The cytotoxicities of S-1452 and AA-2414 were analysed by
MTT assay. IC50 values to S-1452 of PC-9 and PC-9/CDDP
were 1910.2+ 104.8 and 1882+51.8 uM respectively. The IC50
values of AA-2414 for PC-9 and PC-9/CDDP were
686.6+49.2 and 689.0+39.3 gM respectively. There was no
significant difference in the sensitivities of PC-9 and PC-9/
CDDP cells to S-1452 or AA-2414. The sensitivities to CDDP
and CBDCA of PC-9 and PC-9/CDDP cells were evaluated
by MTT assay. Table I shows the effect of S-1452 on the
sensitivities for CDDP of PC-9 and PC-9/CDDP. The IC50
values of CDDP in PC-9 and PC-9/CDDP were 46.2+13.1
and 276.3 +56.4 uM without treatment with S-1452. The
effect of S-1452 on sensitivity to CDDP in a 2 h drug
exposure was evaluated (Table I). IC50 values to CDDP in
PC-9 cells were 21.7+3.2 and 10.l+3.6 Mm when treated
with 250 or 500 gM S-1452 respectively. In PC-9/CDDP cells,
250 ,M and 500 gM S-1452 enhanced the sensitivity by 3.1-
fold and 6.1-fold respectively (Table I). S-1452 enhanced theCDDP sensifivft to TXA2 receptor antagonists
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toxicity of CDDP in a dose-dependent manner. There was no
significant difference between ICs0 value to CDDP of PC-9
cells without S-1452 treatment and that of PC-9/CDDP cells
treated with 500 Mm S-1452. S-1452 also enhanced CBDCA
cytotoxicity in PC-9 cells (Table I). This represented a
significant decrease in IC50 value to CBDCA by the S-1452
treatment. IC50 value to CBDCA for 2 h drug exposure was
0.66+0.18 mM without S-1452 treatment. When treated with
250 or 500 gM S-1452, the sensitivities of PC-9 cells were
increased 1.4-fold and 1.8-fold respectively. PC-9/CDDP cells
treated with CBDCA in the presence of 250 gM or 500 ,uM S-
1452 demonstrated a 2.7- and 3.7-fold increase in cytotoxicity
respectively. The sensitising effect was also dose dependent in
the case of CBDCA. AA-2414 significantly decreased the IC50
values of PC-9 and PC-9/CDDP cells in a dose-dependent
manner (Table II).
Isobolograms at IC50 were made (Figure 2). For
simultaneous exposure to CDDP and S-1452, the combined
data points fell on the left side of envelope or in the envelope
in each cell line (Figure 2a and b). Figure 2c and d showed
the isobologram combined with CDDP and AA-2414. In PC-
9, the combined data points fell in the envelope (Figure 2c)
and those of PC-9/CDDP fell on the left side of envelope or
in the envelope (Figure 2d). This indicates that the effect of
TXA2 receptor antagonists on the sensitivity to CDDP was
supra-additive or additive.
To elucidate the effect of S-1452 on detoxification
mechanisms, we measured GSH contents and total GST
activities of PC-9 and PC-9/CDDP cells with and without S-
1452 treatment. There was no significant change in GSH
content or GST activity by treatment with 500 gM S-1452 for
2 h (Table III).
The kinetics of CDDP accumulation was examined
(Figure 3a). CDDP concentration of 50 gM was chosen for
these studies because. it is approximately equal to the IC50
values for PC-9 cells. Accumulation of CDDP increased
linearly up to 120 min with or without S-1452 treatment.
There was a significant increase in CDDP accumulation in
both cell lines by co-incubation with S-1452. After exposure
to CDDP for 120 min, we also evaluated efflux of CDDP
from PC-9 and PC-9/CDDP cells with or without S-1452
treatment. There was no significant difference in the efflux of
CDDP as a function of S-1452 in each cell line. The effect of
S-1452 on CDDP accumulation was also dose-dependent
(Figure 3b). S-1452 at 250 and 500 gM resulted in 1.1 and
1.4-fold increase in CDDP accumulation in PC-9 cells, and
1.3- and 1.6-fold increase in PC-9/CDDP cells. Accumulation
into PC-9/CDDP treated with S-1452 was approximately
equal to that into PC-9 without the treatment.
To elucidate the mechanism of increase in CDDP
accumulation by S-1452, we determined 86Rb+ influx as an
indicator of Na+, K+-ATPase activity (Figure 4). 86Rb+
influx of PC-9/CDDP was decreased compared with that of
PC-9. When treated with 250 or 500 MM S-1452, 86Rb+ influx
of PC-9 cells was significantly increased 1.3-fold and 1.6-fold
respectively. In PC-9/CDDP cells, 86Rb+ influx was
significantly increased on the treatment by 1.2-fold and 1.5-
fold respectively. The increase in 16Rb± influx in each cell line
was correlated with platinum accumulation (P<0.01).
Discussion
Inherent and acquired resistance to CDDP represents a major
clinical problem in cancer chemotherapy. Several chemicals
have been evaluated for their ability to assist in overcoming
this resistance (Timmer-Bosscha et al., 1992). Morikage et al.
(1993) have reported that amphotericin B enhanced CDDP
cytotoxicity in lung cancer cell lines. Mann et al. (1991) have
reported that forskolin, an adenyl cyclase agonist, and 3-
isobutyl-1-methylxanthine, a phosphodiesterase inhibitor,
increased intracellular accumulation and cytotoxicity of
CDDP. Fujiwara et al. (1990) have reported that GSH
depletion by DL-buthionine-S, R-sulphoximine induced a 1.8-
fold increase in the sensitivity of PC-9 and PC-9/CDDP.
Ethacrynic acid, a specific inhibitor of GST, has also induced
increase in the sensitivity (Kasahara et al., 1991). Pentoxifyl-
line has also been shown to increase anti-tumour activity of
Table I S-1452 modulation of platinum sensitivity of PC-9 and PC-9/CDDP cells
Agent S-1452 (Mm) IC50 value of PC-9 Sensitising effecta IC50 value ofPC-9/CDDP Sensitising effect
CDDP (Mm) 0 46.2+13.lb 276.3+56.4
250 21.7+3.2c 2.1 88.6+38.9c 3.1
500 10.l+3.6d 4.6 45.6+ 10.4d 6.1
CBDCA (mM) 0 0.66+0.18 2.20+1.18
250 0.47+0.14e 1.4 0.83 +0.54e 2.7
500 0.36+0.09f 1.8 0.59+0.3_3 3.7
aSensitising effect isIC50value ofcontrolcells/IC50 valueoftreatedcells. bEachvalueis themean+s.d. (n =9). cp<0.05compared
with IC50 value of PC-9 treated with vehicle. dP<0.05 compared with IC50 value of PC-9 treated with vehicle or 250M S-1452. p<0.05 compared with IC50 value ofPC-9/CDDP treated with vehicle. fP<0.05 compared with IC, value ofPC-9/CDDP treated
with vehicle or 250pM S-1452. The percentage of PC-9 cells when treated with 250 and 500MM S-1452 was 94.3+4.7% and
91.7+5.3%, respectively, while the corresponding values for PC-9/CDDP cells were 97.0+6.0% and 92.0+4.3% respectively.
Table II AA-2414 modulation platinum sensitivity of PC-9 and PC-9/CDDP cells
Agent AA-2414 (pM) IC50 value of PC-9 Sensitising effecta IC50 value of PC-9/CDDP Sensitising effect
CDDP (yM) 0 49.7+6.4b 256.0+26.2
250 30.2+4.3C 1.6 99.4+ 16.0C 2.5
500 14.9+2.8d 3.3 56.5+11.2d 4.5
CBDCA (mM) 0 0.57+0.10 2.32+0.15
250 0.40+0.10e 1.4 1.59+0.15e 1.4
500 0.36+0.091 1.7 1.II+0.05f 2.0
aSensitisingeffectis IC50value ofcontrolcells/IC50 value oftreatedcells.bEachvalueis themean±s.d. (n =9). cP<0.05 compared
with ICs0 value ofPC-9 treated with vehicle. dP<0.05 compared with IC50 value ofPC-9 treated with vehicle or 250 Mm AA-2414.
eP<0.05 compared with IC50 value ofPC-9/CDDP treated with vehicle. fP<0.05 compared with ICso value ofPC-9/CDDP treated
with vehicle or 250 M AA-2414. Survival rates ofPC-9 cells treated with 250 and 500gM AA-2414 were 85.4+3.7 or 79.4+ 1.2% in
PC-9, respectively, while the corresponding values for PC-9/CDDP cells were 88.9+4.2 and 79.6+ 1.6% respectively.CDDP sensitivity to TXA2 receptor antagonists
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Figure 2 Isobologram of CDDP in combination with S-1452 or AA-2414. (a and c) PC-9; (b and d) PC-9/CDDP. (a and b)
Isobologram in combination with S-1452; (c and d) isobologram in combination with CDDP and AA-2414. mode I; - --
mode IIA; - - - mode IIB.
CDDP (Schiano et al., 1991). These studies suggested the
importance of trying to improve present chemotherapy by
enhancing its effect with other chemical agents, as well as
attempting to develop new agents.
In this study we evaluated the effect of TXA2 receptor
antagonists, S-1452 and AA-2414, on the sensitivities of two
non-small-cell lung cancer cell lines to CDDP and CBDCA.
These are highly potent and selective antagonists for the
TXA2 receptor (Dube et al., 1992; Kurokawa et al., 1994).
Treatment with S-1452 or AA-2414 decreased IC50 value to
CDDP and CBDCA in PC-9 and PC-9/CDDP cells (Tables I
and II). Isobologram analysis showed that CDDP had a
supra-additive or additive effect when combined with S-1452
or AA-2414 (Figure 2). These studies demonstrate that TXA2
receptor antagonists affect sensitivity to CDDP and CBDCA.
To evaluate the mechanism(s) of the effect of S-1452 on
the sensitivity to platinum agents, we measured GSH content,
GST activity and platinum accumulation in PC-9 and PC-9/
CDDP. S-1452 had no effect on GSH content and GST
activity of PC-9 and PC-9/CDDP cells (Table III). These data
showed that the sensitising effect of S-1452 did not correlate
with the GSH content or GST activity. S-1452 increased the
platinum accumulation into PC-9 and PC-9/CDDP. An
increase in platinum accumulation was dependent on the
concentration of S-1452 and related to the increase in
sensitivity to CDDP (Figure 3). There was a 40% increase
in platinum accumulation in PC-9 cells and 60% in PC-9/
CDDP cells when treated with 500 giM S-1452. Because
kinetic study showed that there was no difference in the efflux
of platinum from PC-9 and PC-9/CDDP cells, the increase in
influx may result in increase in accumulation. The increase in
platinum influx may explain the S-1452 sensitising effect. To
Table III Glutathione content and glutathione S-transferase activ-
ity of PC-9 cells
PC-9 PC-9/CDDP
(_)a S(+)b S(-) S(+)
GSH content 35.9+1.1c 38.5+1.4 78.8+8.2 72.9+3.3
(nmolmg-1
protein)
GST activity 245+23.6 239.3+ 18.3 205.2+ 18.6 190.2+8.4
(nmolmin- /
mg protein)
aTreated with vehicle. bTreated with 5OO,UM S-1452 for 120min.
cEach value is the mean+s.d. (n =4).
elucidate the mechanism of increase in uptake, we evaluated
the Na+, K+-ATPase activity indicated as a 86Rb+ influx rate
and the effect of the S-1452 (Figure 4). Na+, K+-ATPase
activity of PC-9/CDDP was decreased compared with that of
PC-9. This decrease in Na+, K+-ATPase activity may
explain the decrease in CDDP accumulation in PC-9/
CDDP. Treatment with S-1452 resulted in an increase in
the Na+, K+-ATPase activity in a dose-dependent manner.
This increase may be responsible for the increase in platinum
accumulation and sensitising effect of TXA2 receptor
antagonists.
The mechanism by which CDDP enters tumour cells
remains unknown. It has been postulated that CDDP enters
the cells by passive diffusion (Mann et al., 1990). However,
many studies showed that CDDP accumulation could be
specifically stimulated and inhibited by pharmacological
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Figure 3 Accumulation of platinum into PC-9 and PC-9/CDDP.
(a) time course study. Cells were treated with 50 gm CDDP with
500 gm S-1452 or vehicle for 60 or 120 mm. After incubation for
120 min, cells were washed and incubated for an additional 60 or
120 mn. 0, PC-9 with vehicle; 0, PC-9 treated with 500 hm S-
1452; i, PC-9/CDDP with vehicle; , PC-9/CDDP treated
with 500 gm S-1452. *P<0.05 compared with PC-9 or PC-9/
CDDP cells treated with vehicle. (b) effect of S-1452 on the
accumulation of platinum into PC-9 and PC-9/CDDP was
evaluated. Cells were treated with 50 gm CDDP with vehicle
(LIp) or with 250pM g or500PC m (lls1) of S-N1452 for
120 min *P<0.05.
agents (Andrews et al., 1991). These results suggest that some
component of CDDP accumulation must be mediated by a
transport mechanism. Andrews et al. (1991) reported that
ouabain, an Nas ,Kt -ATPase inhibitor, inhibited CDDP
accumulation. Ohmori et al. (1994) reported that platinum
accumulation in PC-14/0B300, which showed 1.9-fold
resistance to cytotoxicity of ouabain, was increased
compared with that in parent PC-14 cells. Nae, KT-ATPase
activity and mRNA expression of Na, K+-ATPase were
increased in PC-14/0B300 compared with PC-14. These
studies suggested that Na+, K+-ATPase activity might be
important in CDDP accumulation. In this study, Na+, K'-
ATPase activity indicated that a 86Rb' influx was stimulated
by treatment with S-1452 in each cell line. These data
suggested that Na>, K'-ATPase activity may be a
determinant of CDDP accumulation in PC-9 and PC-9/
CDDP. Treatment with a TXA2 receptor antagonist, S-1452,
might stimulate Na+, K+-ATPase activity and induce
300 [ [-7
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ET
cm
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Figure 4 Na+, K+-ATPase activity as a Rb influx of PC-9 and
PC-9/CDDP. Cells were treated with vehicle (L ) or with
250 /iM (M) or 500 gM (H1 ) of S-1452 for 60 min. *P<0.05.
increase in platinum accumulation, which may result in
enhancement of CDDP cytotoxicity. Although these findings
might explain the decrease in ICs0 values to CDDP and
CBDCA, the mechanism(s) of synergistic effect induced by
TXA2 receptor antagonists may not be clear. Further studies
that address other possible mechanisms of sensitivity to
CDDP, such as those that involve the effect of platinum
agents on DNA damage and its repair, cell cycle or
apoptosis, are needed.
TXA2 is one of the arachidonic acid metabolites generated
by cyclo-oxygenase and TX synthetase that is hydrolised to
an inactive substance, thromboxane B2 (TXB2), with a
chemical half-time of 30 s. TXA2 is known to induce platelet
aggregation, vasoconstriction and bronchoconstriction (Oates
et al., 1988) TXA2 receptor antagonists and TX synthetase
inhibitors are effective for such diseases (Oates et al., 1988).
Nigam et al. (1985) have proposed that 6-keto-prostaglandin
Fic. (an inactive metabolite of prostaglandin 12/TXB2 ratio
might be an indicator for tumour growth and metastasis.
TXA2 has also been shown to play an important role in
tumour proliferation (Nigam et al., 1990). Ushikubi et al.
(1993) have reported that treatment with a TXA2 agonist,
9,11-epithio-l 1,12-methano-thromboxane A2, caused DNA
fragmentation in thymocytes, and this change was blocked by
S-1452. Teicher et al. (1994) have reported that cyclo-
oxygenase inhibitors enhance cytotoxicity of CDDP in vivo.
These data suggest that TXA2 and TXA2 receptor may be
relevant to cancer cell growth, apoptosis and cell death. In
this study, TXA2 receptor antagonists showed additive or
synergistic effect when combined with CDDP. TXA2 receptor
antagonists used in our study might have some effect on cell
cycle or apoptosis and these effects might result in a
synergistic effect of TXA2 receptor antagonists when
combined with CDDP.
In conclusion, TXA2 receptor antagonists decreased the
IC50 value to CDDP and CBDCA in non-small-cell lung
cancer cell lines. This effect was supra-additive or
additive. An increase in platinum accumulation owing to
increased Na+, K+-ATPase may be responsible for the
enhanced efficacy of platinum. Our data suggest that
TXA2 receptor antagonists, such as S-1452 or AA-2414,
may have a role in enhancing CDDP-based chemotherapy
for lung cancer.
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